trans-Vaccenic Acid-d13
(Synonyms: C18:1(11E)-d13, C18:1 n-7-d13, trans-11-Octadecenoic Acid-d13) 目录号 : GC48196
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
trans-Vaccenic acid-d13 is intended for use an internal standard for the quantification of trans-vaccenic acid by GC- or LC-MS. trans-Vaccenic acid is an ω-7 fatty acid that has been found in bovine milk fats.1 Dietary administration of trans-vaccenic acid (1% w/w) reduces total body fat, mesenteric fat, and adipocyte size, increases inguinal fat mass, and decreases intestinal and hepatic triglyceride secretion in a rat model of obesity with features of metabolic syndrome.2 It decreases hepatocellular ballooning and steatosis, markers of non-alcoholic fatty liver disease (NAFLD), in the same model. Dietary administration of a butter enriched with trans-vaccenic acid decreases serum cholesterol levels and the formation of aortic atherosclerotic lesions in Ldlr-/- mice.3
1.Santora, J.E., Palmquist, D.L., and Roehrig, K.L.Trans-vaccenic acid is desaturated to conjugated linoleic acid in miceJ. Nutr.130(2)208-215(2000) 2.Jacome-Sosa, M.M., Borthwick, F., Mangat, R., et al.Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndromeJ. Nutr. Biochem.25(7)692-701(2014) 3.Bassett, C.M., Edel, A.L., Patenaude, A.F., et al.Dietary vaccenic acid has antiatherogenic effects in LDLr-/- miceJ. Nutr.140(1)18-24(2010)
| Cas No. | N/A | SDF | |
| 别名 | C18:1(11E)-d13, C18:1 n-7-d13, trans-11-Octadecenoic Acid-d13 | ||
| Canonical SMILES | OC(CCCCCCCCC/C=C/C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])(C([2H])([2H])[2H])[2H])=O | ||
| 分子式 | C18H21D13O2 | 分子量 | 295.5 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 100 mg/ml,Ethanol:PBS (pH 7.2): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3841 mL | 16.9205 mL | 33.8409 mL |
| 5 mM | 0.6768 mL | 3.3841 mL | 6.7682 mL |
| 10 mM | 0.3384 mL | 1.692 mL | 3.3841 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。